FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2923689870> ?p ?o ?g. }

• W2923689870 endingPage "885" @default.
• W2923689870 startingPage "877" @default.
• W2923689870 abstract "BCR fused ABL kinase is the critical driving oncogene for chronic myeloid leukemia (CML) and has been extensively studied as the drug discovery target in the past decade. The successful introduction of tyrosine kinase inhibitors (TKI) such as Imatinib, Dasatinib and Bosutinib has greatly improved the CML patient survival rate. However, upon the chronic treatment, a variety of TKI resistant mutants, such as the V299L mutant which has been found in more and more patients with the high-throughput sequencing technology, are observed, although the incidence is still considered rare compared to the more prevalent gatekeeper T315I mutant. However, with the progress of the precision medicine concept, the rare mutation (or the orphan drug target) has attracted more and more attention. Here we report a novel type II BCR-ABL kinase inhibitor, CHMFL-ABL-039, which not only displayed great potency (IC50: 7.9 nM) and selectivity (S score (1) = 0.02) against native ABL kinase among other kinases in the kinome, but also exhibited great potency (IC50: 27.9 nM) and selectivity against Imatinib-resistant V299L mutant among other frequently observed ABL kinase mutants. CHMFL-ABL-039 has demonstrated greater efficacies than Imatinib regarding to the anti-proliferation, inhibition of the signaling pathway, arrest of cell cycle progression, induction of apoptosis in vitro and suppression of the tumor progression in vivo in the native and V299L mutated BCR-ABL kinase-driven cells/xenograft models. It would be a useful pharmacological tool to study the TKI resistant ABL V299L mutant-mediated pathology and provide a potential precise treatment approach for this orphan CML subtype in the precision medicine era." @default.
• W2923689870 created "2019-04-01" @default.
• W2923689870 creator A5000728648 @default.
• W2923689870 creator A5009717743 @default.
• W2923689870 creator A5012278873 @default.
• W2923689870 creator A5014255862 @default.
• W2923689870 creator A5014661038 @default.
• W2923689870 creator A5025406557 @default.
• W2923689870 creator A5029503387 @default.
• W2923689870 creator A5031645533 @default.
• W2923689870 creator A5035282947 @default.
• W2923689870 creator A5036613307 @default.
• W2923689870 creator A5052437697 @default.
• W2923689870 creator A5056391726 @default.
• W2923689870 creator A5058132534 @default.
• W2923689870 creator A5058484759 @default.
• W2923689870 creator A5062652934 @default.
• W2923689870 creator A5062755510 @default.
• W2923689870 creator A5069044551 @default.
• W2923689870 creator A5070433780 @default.
• W2923689870 creator A5071417968 @default.
• W2923689870 creator A5072940513 @default.
• W2923689870 creator A5083895623 @default.
• W2923689870 date "2019-03-20" @default.
• W2923689870 modified "2023-09-22" @default.
• W2923689870 title "Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)" @default.
• W2923689870 cites W1719330231 @default.
• W2923689870 cites W190597540 @default.
• W2923689870 cites W1964445294 @default.
• W2923689870 cites W1971651191 @default.
• W2923689870 cites W1980060129 @default.
• W2923689870 cites W1993923385 @default.
• W2923689870 cites W2016656445 @default.
• W2923689870 cites W2051806138 @default.
• W2923689870 cites W2078327579 @default.
• W2923689870 cites W2079398727 @default.
• W2923689870 cites W2079687106 @default.
• W2923689870 cites W2086286404 @default.
• W2923689870 cites W2097946794 @default.
• W2923689870 cites W2109030976 @default.
• W2923689870 cites W2124196948 @default.
• W2923689870 cites W2156373035 @default.
• W2923689870 cites W2426790149 @default.
• W2923689870 cites W2558292485 @default.
• W2923689870 cites W2593028314 @default.
• W2923689870 cites W2750145485 @default.
• W2923689870 cites W85529956 @default.
• W2923689870 doi "https://doi.org/10.1080/15384047.2019.1579958" @default.
• W2923689870 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6606039" @default.
• W2923689870 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30894066" @default.
• W2923689870 hasPublicationYear "2019" @default.
• W2923689870 type Work @default.
• W2923689870 sameAs 2923689870 @default.
• W2923689870 citedByCount "4" @default.
• W2923689870 countsByYear W29236898702021 @default.
• W2923689870 countsByYear W29236898702022 @default.
• W2923689870 crossrefType "journal-article" @default.
• W2923689870 hasAuthorship W2923689870A5000728648 @default.
• W2923689870 hasAuthorship W2923689870A5009717743 @default.
• W2923689870 hasAuthorship W2923689870A5012278873 @default.
• W2923689870 hasAuthorship W2923689870A5014255862 @default.
• W2923689870 hasAuthorship W2923689870A5014661038 @default.
• W2923689870 hasAuthorship W2923689870A5025406557 @default.
• W2923689870 hasAuthorship W2923689870A5029503387 @default.
• W2923689870 hasAuthorship W2923689870A5031645533 @default.
• W2923689870 hasAuthorship W2923689870A5035282947 @default.
• W2923689870 hasAuthorship W2923689870A5036613307 @default.
• W2923689870 hasAuthorship W2923689870A5052437697 @default.
• W2923689870 hasAuthorship W2923689870A5056391726 @default.
• W2923689870 hasAuthorship W2923689870A5058132534 @default.
• W2923689870 hasAuthorship W2923689870A5058484759 @default.
• W2923689870 hasAuthorship W2923689870A5062652934 @default.
• W2923689870 hasAuthorship W2923689870A5062755510 @default.
• W2923689870 hasAuthorship W2923689870A5069044551 @default.
• W2923689870 hasAuthorship W2923689870A5070433780 @default.
• W2923689870 hasAuthorship W2923689870A5071417968 @default.
• W2923689870 hasAuthorship W2923689870A5072940513 @default.
• W2923689870 hasAuthorship W2923689870A5083895623 @default.
• W2923689870 hasBestOaLocation W29236898701 @default.
• W2923689870 hasConcept C121608353 @default.
• W2923689870 hasConcept C125418893 @default.
• W2923689870 hasConcept C184235292 @default.
• W2923689870 hasConcept C2777413986 @default.
• W2923689870 hasConcept C2777583451 @default.
• W2923689870 hasConcept C2778208673 @default.
• W2923689870 hasConcept C2778729363 @default.
• W2923689870 hasConcept C2778820342 @default.
• W2923689870 hasConcept C2779536868 @default.
• W2923689870 hasConcept C2780381907 @default.
• W2923689870 hasConcept C3019892230 @default.
• W2923689870 hasConcept C42362537 @default.
• W2923689870 hasConcept C502942594 @default.
• W2923689870 hasConcept C54174078 @default.
• W2923689870 hasConcept C54355233 @default.
• W2923689870 hasConcept C62478195 @default.
• W2923689870 hasConcept C86803240 @default.
• W2923689870 hasConcept C95444343 @default.
• W2923689870 hasConcept C98274493 @default.

• next